Literature DB >> 10436507

[Amputations and mortality in elderly insulin-treated patients with type 2 diabetes].

M Spraul1, A M Schönbach, I Mühlhauser, M Berger.   

Abstract

The diabetic foot syndrome has a strong impact on the morbidity of elderly patients with type 2 diabetes, since diabetics have a 22-fold higher amputation rate. The aim of this study was to conduct a prospective evaluation of elderly insulin-treated patients with type 2 diabetes, giving special consideration to the diabetic foot syndrome. 94 consecutively admitted patients (mean age 68 years; mean diabetes duration 13 years) were re-evaluated 2, 5 and 10 years after participation in a 5-day insulin treatment and teaching programme for patients with type 2 diabetes. During the 10-year follow-up period 60 (64%) patients had died. Of the remaining 34 patients 33 were evaluated personally or by phone. All patients still alive had no acute foot complications and no amputations during the 10-year follow-up period. In these patients an acceptable level of metabolic control and acute metabolic decompensations was found. However, in 55 deceased patients (no data were available for 5 patients) 20 above-knee amputations (1 patient on both legs) and 2 fore-foot amputations were performed. This shows that severe complications as amputations associated with high mortality will be grossly underestimated, unless deceased patients are included in follow-up studies. An improved care for the feet of elderly insulin-treated patients is needed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10436507

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  2 in total

1.  [Epidemiology and classification of diabetic foot syndrome].

Authors:  J Teichmann; D Sabo
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

2.  [Homologous vein transplantation in cruropedal arterial reconstruction].

Authors:  B Luther; K M Balzer; P Reinecke; R Wassmuth; W Sandmann
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.